Prohost BiotechResearch Platform

Home Articles Trick or TradeAgenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Trick or Trade

Premium

Agenus: Could It Be a Resurrection? See Also: Prohost Performing Stocks

Agenus Announced Data from Phase 2 Trials of Balstilimab Agenus ( AGEN ) immuno-oncology company announced that data from two Phase 2 trials of balstilimab alone and in combination with zalifrelimab w...

P

Prohost Biotech

September 2, 2020

1 min read

3

0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles

Expert analysis

Research reports

Tags

Comments (0)

Please sign in to join the discussion

Related Articles

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech BioNTech ( BNTX ) announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in patients with HER2-expressing, advanced endometrial cancer whos...

Prohost Biotech

Apr 17, 2026

Zymeworks Inc Question and Answer

Zymeworks Inc Q & A Q: What’s the story about Zymeworks entering into a deal with Royalty Pharma? A: Zymeworks and Royalty Pharma have already entered into $250 Million Royalty-Backed Note Financing....

Prohost Biotech

Mar 12, 2026

Milestone Receives FDA Approval of CARDAMYST™ as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia

Milestone in the NEWS MONTREAL and CHARLOTTE, Milestone ® ( MIST ) announced that the U.S. FDA approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for...

Prohost Biotech

Dec 16, 2025